4.32
-0.03 (-0.69%)
| Previous Close | 4.35 |
| Open | 4.34 |
| Volume | 353,096 |
| Avg. Volume (3M) | 788,743 |
| Market Cap | 202,359,184 |
| Price / Sales | 1.76 |
| Price / Book | 0.900 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Profit Margin | -35.28% |
| Operating Margin (TTM) | -86.92% |
| Diluted EPS (TTM) | -1.24 |
| Quarterly Revenue Growth (YOY) | -5.40% |
| Total Debt/Equity (MRQ) | 11.51% |
| Current Ratio (MRQ) | 8.29 |
| Operating Cash Flow (TTM) | -28.89 M |
| Levered Free Cash Flow (TTM) | -6.46 M |
| Return on Assets (TTM) | -9.38% |
| Return on Equity (TTM) | -14.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Quanterix Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | -1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.40 |
|
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 7.66% |
| % Held by Institutions | 89.70% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Easterly Investment Partners Llc | 30 Jun 2025 | 1,083,635 |
| 52 Weeks Range | ||
| Median | 5.00 (15.74%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 11 Aug 2025 | 5.00 (15.74%) | Hold | 4.58 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SRIRAM VANDANA | - | 5.78 | -229 | -1,324 |
| TOLOUE MASOUD | - | 5.78 | -1,242 | -7,179 |
| Aggregate Net Quantity | -1,471 | |||
| Aggregate Net Value ($) | -8,502 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 5.78 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TOLOUE MASOUD | Officer | 15 Oct 2025 | Disposed (-) | 1,242 | 5.78 | 7,179 |
| SRIRAM VANDANA | Officer | 15 Oct 2025 | Disposed (-) | 229 | 5.78 | 1,324 |
| Date | Type | Details |
|---|---|---|
| 21 Aug 2025 | Announcement | Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit |
| 11 Aug 2025 | Announcement | Quanterix to Present at the Canaccord Genuity 45th Annual Growth Conference |
| 07 Aug 2025 | Announcement | Quanterix Releases Financial Results for the Second Quarter of 2025 |
| 04 Aug 2025 | Announcement | Quanterix Announces Cooperation Agreement with Kent Lake Capital |
| 04 Aug 2025 | Announcement | Quanterix To Report Second Quarter 2025 Financial Results on August 7, 2025 |
| 28 Jul 2025 | Announcement | Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |